In this issue:
DYNAMIC: post-surgical ctDNA-guided adjuvant chemotherapy in colon cancer
Acquired genomic alterations rare after front-line cetuximab/chemotherapy
Induction PD-1 blockade promising for dMMR rectal cancer
Global CRC incidence and mortality expected to rise substantially
Promising results for neoadjuvant galunisertib plus chemoradiation for rectal cancer
AtezoTRIBE: FOLFOXIRI/bevacizumab ± atezoliumab for metastatic CRC
Intensifying chemotherapy no benefit in metastatic RAS/BRAF wild-type disease
Efficacy of FOLFIRI plus cetuximab or bevacizumab, according to age
Initial use of irinotecan in chemotherapy regimen superior to delay until progression
FOLFOX ± panitumumab after resection of liver metastases
Please login below to download this issue (PDF)